Because of its involvement in autoimmune conditions, IL-17 inhibition is investigated as possible treatment for rheumatoid arthritis, psoriasis and inflammatory bowel disease. As of early 2012, clinical trials of IL-17 antibodies against psoriasis have shown promising results in Phase II.
Interleukin 17 is a cytokine that acts as a potent mediator in delayed-type reactions by increasing chemokine production in various tissues to recruit monocytes and neutrophils to the site of inflammation, similar to Interferon gamma. IL-17 is produced by T-helper cells and is induced by IL–23 which results in destructive tissue damage in delayed-type reactions. Interleukin 17 as a family functions as a proinflammatory cytokine that responds to the invasion of the immune system by extracellular pathogens and induces destruction of the pathogen’s cellular matrix. Interleukin 17 acts synergistically with tumor necrosis factor and interleukin-1.
In the frame of its R&D activities Biomedcode has created TghuIL17A mice that have normally regulated expression of huIL17A. TghIL17A mice in combination with induced psoriasis protocols form a drug efficacy evaluation platform for testing anti-huIL17A therapeutics.